Eureka In the News

November 1, 2021 – Kalkine Media

Imugene Partners with Eureka Therapeutics for Solid Tumour Treatment, Stock Jumps


JULY 21, 2021 – BioSpace

BioSpace logoEureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer


JULY 8, 2021 – Informa Pharma Intelligence

Tech Transfer Roundup: Sanofi Gets IP For Multiple Myeloma From Memorial Sloan Kettering


JULY 6, 2021 – FIERCEBIOTECH

   | Sanofi puts $1B-plus on the table for Eureka's multiple myeloma treatment candidate


JULY 6, 2021 – Biocentury

BioCentury logo| Sanofi looks to emerging target for multiple myeloma


MAY 25, 2021 – Endpoints News

Endpoints News logo| Researchers in biotech, academia and Big Pharma are offering puzzle pieces to crack CAR-T for solid tumors. Will they ever snap together?


FEBRuARY 12, 2021 – BioSpace

BioSpace logoIntranasal Approaches Have Potential As Vaccines & Therapies for COVID-19


FEBRuARY 3, 2021 – European Pharmaceutical Review

    BioSpace logo    Is intranasal drug delivery the best way to administer COVID-19 therapeutics


December 22, 2020 – FIERCEpharma

   | 2021 forecast: Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19


December 21, 2020 – Biocentury

BioCentury logo| Reversible control of CAR expression; plus an inflammation-reducing mAb, two intranasal COVID-19 treatments and more


December 15, 2020 – Pharmaceutical Business Review

 | Eureka Therapeutics announces preclinical results of InvisiMask human antibody nasal spray against SARS-CoV-2 infection


December 14, 2020 – FIERCEBIOTECH

   | COVID-19 nasal spray from Eureka Therapeutics protects mice against infection


December 14, 2020 – BioSpace

BioSpace logoEureka’s InvisiMask™ Anti-SARS-CoV-2 Nasal Spray Protects for 10 Hours in Preclinical Results


OCTOBER 9, 2020 – Precision Oncology News

Eureka Therapeutics Begins Trial Assessing T-cell Therapy in Certain Liver Cancer Patients


august 17, 2020 – Endpoints News

Endpoints News logo| Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future


JULY 20, 2020 – BioSpace

BioSpace logoJW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China


MARCH 20, 2020 – XCONOMY

| Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies


MARCH 17, 2020 – Endpoints News

Endpoints News logo| Rick Klausner's Lyell partners, helps fund Eureka's work on cell therapies; Blueprint bounces higher on PhII


MARCH 17, 2020 – BioSpace

BioSpace logoEureka Therapeutics Completes $45 Million Series E Financing and Enters Into Strategic Collaboration With Lyell Immunopharma


MARCH 17, 2020 – Biocentury

BioCentury logo| Eureka Tackles Major Challenges for T Cells in Solid Tumors with $45M E Round, Lyell Deal


DECEMBER 20, 2018 – Biocentury

BioCentury logo| Cell therapies seek solid ground


November 1, 2018 – scientific american

Scientific American logo| Frontiers in T Cell Therapy


SEPTEMBER 21, 2018 – Biocentury

BioCentury logo| Eureka's ET140202 leads to tumor regression in Phase I for HCC


September 11, 2018 – South China Morning Post

South China Morning Post logo| Chinese doctor’s near-miracle recovery after cancer immunotherapy shows the promise new treatment holds


September 6, 2018 – Endpoints News

Endpoints News logo| A new CAR-T is credited with a ‘surprising’ impact in tiny study of advanced liver cancer — raising hopes on solid tumors


September 6, 2018 – China News (State-owned news agency)

China News logo| 美华人科学团队发布T细胞免疫疗法治疗晚期肝癌成果


September 5, 2018 – Bloomberg

bloomberg logo| Eureka’s CAR-T Drug Shrinks Liver Cancer for Some in Small Study


August 23, 2018 – Biocentury

BioCentury logo| Cancer Overview


August 17, 2018 – Contract Pharma

Contract Pharma logo| Eureka, Memorial Sloan Kettering Pioneer New CAR-T Technology


August 17, 2018 – PMLive

PM Live logo| Armoured CAR ‘could overwhelm solid tumour resistance’


August 16, 2018 – MedCity News

MedCity News logo| Researchers develop ‘armored’ CAR-T with potential against solid tumors


July 20, 2018 – BioCentury

BioCentury logo| Boehringer Exercises Option For Eureka’s TCR-Mimicking Antibodies


July 18, 2018 – The Pharma letter

the pharmaletter  logo| Boehringer exercises option to license novel TCRm antibodies


June 18, 2018 – Contract Pharma

GEN logo| Growing Antibody Industry in China Sees Major Opportunities.


june 15, 2018 – BioCentury

BioCentury logo| Eureka reports Phase I response data for anti-CD19 T cell therapy in lymphoma


Janaury 26, 2018 – BioCentury

BioCentury logo| Eureka Raises $60M Series D


Janaury 24, 2018 – Silicon Valley Business Journal

Silicon Valley Business Journal logo| The Funded: 10 Bay Area startups raise millions


January 24, 2018 – Fortune

Fortune logo| Eureka Therapeutics Inc. raised $60 million in Series D funding


January 22, 2018 – FierceBiotech

Fierce Biotech logoEureka nets $60M to take T-cell therapy into the clinic


January 22, 2018 – BioSpace

BioSpace logo| Bay Area’s Eureka Therapeutics Banks $60M


January 22, 2018 – Reuters

Reuters logo| BRIEF-Eureka Therapeutics Closes $60 Mln In Series D Financing


December 6, 2017 – BioCentury

BioCentury logo| Juno Licenses Gamma Secretase Inhibitor Related IP


December 1, 2017 – Lymphoma News Today

Lymphoma News Today logoEureka Technologies Receives FDA’s OK to Move T-cell Therapy into Clinical Trials


July 20, 2017 – BioCentury

BioCentury logo| Eureka a moment for TCR Mimics


June 12, 2017 – Liver Disease News

Liver Disease News logo| Eureka, City of Hope to Conduct Phase 1 Trial of Investigational CAR T-cell Therapy for Liver Cancer


September 20, 2016 – Seeking Alpha

Seeking Alpha logo| Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target


August 6, 2016 – BioCentury

BioCentury logo| Eureka Therapeutics, Memorial Sloan Kettering, Juno Therapeutics Deal


August 5, 2016 – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology News logo| Juno Licenses BCMA from MSK, Eureka Therapeutics


JUNe 22, 2015 – Biocentury

BioCentury logo| Boehringer Ingelheim, Eureka Therapeutics deal


May 22, 2015 – Xconomy

Xconomy logo| West Coast Biotech Roundup: Illumina, Veracyte, Otonomy, Kite & More


November 21, 2014 – The E’Ville Eye

The E'ville Eye logo| Plum Organics, Eureka Therapeutics & Interior Designer Lauren Geremia


September 29, 2014 – BioCentury

| Eureka Raises $21M In C Round


September 24, 2014 – San Francisco Business Times

San Francisco Business Times logo| Emeryville Cancer Drug Developer Lands $21M From Chinese, Other Investors


September 24, 2014 – FierceBiotech

Fierce Biotech logo| Novartis-Partnered Eureka Rounds Up $21M Round For Immuno-Oncology Drug Research


September 23, 2014 – WSJ Venture Capital 

WSJ Venture Capital logo| Eureka Therapeutics Raises $21M Series C Financing


September 23, 2014 – MedCity News

Med City News logo| Startup Gets $21M For Monoclonal Antibody That Reaches Inside The Cancer Cell


February 3, 2014 – BioCentury

BioCentury logo| Eureka Therapeutics, Novartis, Memorial Sloan Kettering Deal


MARCH 28, 2013 – BioCentury

BioCentury logo| mAb attack on WT1